SCHEMBL4902491

SCHEMBL4902491

C=COC(=O)c1ccc(OC(C)=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 5/20 0.53
HSD17B10 Q99714 1/20 0.51
LMNA P02545 4/20 0.50
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ESR1 P03372 1/20 0.46
PGR P06401 1/20 0.46
CHRM2 P08172 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
AR P10275 1/20 0.46
CHRM1 P11229 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
MAPT P10636 4/20 0.46
POLB P06746 2/20 0.46
PKM P14618 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
TTR P02766 1/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12904282 0.84 THRB (0.49) HSD17B10LMNAMEN1KMT2AMAPT
SCHEMBL24293719 0.83 ELANE (0.50) ELANEHSD17B10LMNAMEN1KMT2A
SCHEMBL28447830 0.83 KMT2A (0.59) LMNAMEN1KMT2AMAPTPKM
Acetic Acid SCHEMBL27275952 0.83 TSHR (0.40) LMNAMEN1KMT2AESR1MAPT
SCHEMBL295796 0.82 ALDH1A1 (0.40) LMNAMEN1KMT2AESR1MAPT
Acetone SCHEMBL7597623 0.82 CA1 (0.58) LMNAMEN1KMT2AMAPTPKM
SCHEMBL1579882 0.81 CA1 (0.62) ELANELMNAMEN1KMT2AMAPT
SCHEMBL4902264 0.81 KMT2A (0.60) ELANEHSD17B10LMNAMEN1KMT2A
SCHEMBL19506924 0.81 PARP10 (0.48) HSD17B10LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL9312034 0.81 MAPT (0.48) LMNAKMT2AMAPTPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130299747-A1 CURATIVES FOR EPOXY COMPOSITIONSERS DESIGNER MOLECULES, INC. 2013-11-14 US disclosed
US-20130299747-A1 CURATIVES FOR EPOXY COMPOSITIONSERS DESIGNER MOLECULES, INC. 2013-11-14 US disclosed
US-20130199724-A1 CURATIVES FOR EPOXY COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2013-08-08 US disclosed
US-20130199724-A1 CURATIVES FOR EPOXY COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2013-08-08 US disclosed
US-8431655-B2 Curatives for epoxy compositions DESIGNER MOLECULES, INC. (US) 2013-04-30 US disclosed
US-8431655-B2 Curatives for epoxy compositions DESIGNER MOLECULES, INC. (US) 2013-04-30 US disclosed
US-20100249276-A1 CURATIVES FOR EPOXY COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2010-09-30 US disclosed
US-20100249276-A1 CURATIVES FOR EPOXY COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2010-09-30 US disclosed
US-20100113643-A1 CURATIVES FOR EPOXY ADHESIVE COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2010-05-06 US disclosed
US-20100113643-A1 CURATIVES FOR EPOXY ADHESIVE COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2010-05-06 US disclosed
CN-1455792-A Liquid crystalline thermosets from ester, ester-imide and ester-amide oligomers NASA (US) 2003-11-12 CN disclosed
US-20030152623-A1 Responsive microgel and methods related thereto SUPRATEK PHARMA INC. (CA) 2003-08-14 US disclosed
WO-2003063909-A1 RESPONSIVE MICROGEL AND METHODS RELATED THERETO SUPRATEK PHARMA INC. (US) 2003-08-07 WO disclosed
EP-0910351-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. Searle & Co. (US) 1999-04-28 EP disclosed
US-5898042-A COMPOSITION COMPRISING CORE/SHELL FLUORINE-CONTAINING COPOLYMER DISPERSED IN AQUEOUS MEDIUM TOAGOSEI CO., LTD. (JP) 1999-04-27 US disclosed
EP-0907666-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. Searle & Co. (US) 1999-04-14 EP disclosed
WO-1997049736-A2 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. SEARLE AND CO. (US) 1997-12-31 WO disclosed
WO-1997049387-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. SEARLE AND CO. (US) 1997-12-31 WO disclosed
EP-0675182-B1 Aqueous fluororesin coating composition and process for producing same TOAGOSEI CO LTD (JP) 1997-07-16 EP disclosed
EP-0675182-A1 Aqueous fluororesin coating composition and process for producing same TOAGOSEI CO., LTD. (JP) 1995-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249276-A1 CURATIVES FOR EPOXY COMPOSITIONS ALOX5, LTC4S, ALOX15B ELANE 309/4885HSD17B10 551/4885LMNA 3810/4885
US-20100113643-A1 CURATIVES FOR EPOXY ADHESIVE COMPOSITIONS ALOX5, LTC4S, ALOX15B ELANE 281/4885HSD17B10 548/4885LMNA 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.